FDA Approves METFORMIN HYDROCHLORIDE — Camber Pharmaceuticals, Inc.
Camber Pharmaceuticals has received FDA approval for its generic Metformin HCl for oral administration, potentially generating additional revenue through increased generic competition to branded competitors. This approval, formalized on March 13, 2025, is expected to boost revenues by leveraging insured patient demand for cost-effective diabetes treatments.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed